Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Comparison: Intranasal vs. Other Administration Routes for Semax in Animal Studies

Intranasal Moderate-Good Yes (olfactory/trigeminal) Low-Moderate Yes — most common Subcutaneous Low (BBB limiting) Partial (slow, limited) Low Yes — used in some studies Intraperitoneal Low-Moderate (BBB limiting) Partial Occasionally Intravenous Low (rapid de

This comparison does not assign a generated winner or score.

  • Intranasal
  • Moderate-Good
  • Yes (olfactory/trigeminal)
  • Low-Moderate
  • Yes — most common
  • Subcutaneous
  • Low (BBB limiting)
  • Partial (slow, limited)
  • Low
  • Yes — used in some studies
  • Intraperitoneal
  • Low-Moderate (BBB limiting)
  • Partial
  • Occasionally
  • Intravenous
  • Low (rapid degradation)
  • No (requires BBB crossing)
  • High
  • Rare
  • Intracerebroventricular
  • High (direct CNS)
  • N/A (direct injection)
  • Very High
  • Rare, specialized studies
  • For the vast majority of Semax preclinical neuroscience research, intranasal delivery offers the best balance of CNS delivery efficiency and technical accessibility.